![]() ![]() However, the performance of COVID-19 mRNA vaccines in hematological malignancy patients is unknown, as these individuals were excluded from COVID-19 vaccine clinical trials 9, 10. Such patients should be therefore be prioritized for primary prevention of COVID-19 via vaccination 8. These patients have also been shown to develop prolonged shedding of infectious severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), often lasting several months, and have been implicated in being sources of novel SARS-CoV-2 variants 4- 7. Patients with hematologic malignancies are at high risk for coronavirus disease 2019 (COVID-19)-related complications, with mortality rates exceeding 30% 1- 3.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |